In a new white paper by ProMach Pharma product brand WLS, Michael Mora delves into one of the key challenges faced by pharmaceutical manufacturers in complying with the Drug Supply Chain Security Act (DSCSA). The DSCSA aims to enhance the security and traceability of prescription drugs in the supply chain, requiring manufacturers to serialize prescription drug packages with unique product identifiers, including serial numbers, for tracking and tracing purposes. This process often leads to disruptions and rejected products due to extensive inspections and encoding of information. To address this challenge, Mora suggests the adoption of offline label printing.
Offline label printing operates independently from the main production line, reducing disruptions and enabling continuous production for maximum output. It also incorporates high-resolution inkjet systems with advanced inspection techniques like the line scan camera, allowing for thorough defect detection and rectification before reaching the final assembly stage. This results in a significant reduction in waste and rework. Additionally, offline label printing presents a cost-saving advantage for manufacturers with multiple label heads, eliminating the need for separate coding systems and streamlining resource allocation.
Read the full white paper below for more benefits of offline label printing improving OEE. Manufacturers can strategically incorporate these processes to optimize their production operations and swiftly adapt to evolving market demands. The insights from this white paper offer valuable considerations for those looking to enhance their packaging line operation in the pharma packaging industry.